tga bpc 157 approval status australia Australian Regulatory Process for Medical and IVD Devices Full article: Australian access to

Overview BB10 combines two of the most extensively studied tissue repair peptides BPC-157 (CAS 137525-51-0) and Thymosin Beta-4 / TB500 (CAS 885340-08-9) co-lyophilized at a 1:1 ratio (5mg:5mg) in a single vial

According to a comprehensive aggregation of all the scientific data on BPC-157 to date, the following benefits have been observed in rats [2]: Exerts protective effects during damaging surgical procedures or administration of a toxic substance Heals organ, bone, and joint damage Treats stomach ulcers Possesses anti-inflammatory properties While the side effects of BPC-157 appear to be non-existent, very little research involving human test subjects exists [3]: While BPC-157 is not approved by the FDA, it can be purchased by researchers and, in rare cases, can be prescribed by a doctor in certain circumstances

DSIP is generally considered safe when used properly, but some potential side effects or risks include: Mild headaches or dizziness

MartinTG IIIRichterJVijRColeCAtanackovicDZonderJ